Related coverage linked through entity extraction aliases.
Apr 24, 2026
Danaher agreed to acquire Masimo for $9.9 billion, paying $180 per share to expand its diagnostics portfolio into blood oxygen monitoring and patient monitoring devices. Danaher also launched nearly €3 billion in senior notes to help fund the deal, which is expected to close by the second half of 2026.
Apr 22, 2026
The mRNA synthesis and manufacturing market is projected to grow from USD 2.23 billion in 2024 to USD 2.96 billion by 2029 at a 5.8% CAGR. Consumables led in 2023, while Asia Pacific is expected to be the fastest-growing region.
Apr 21, 2026
Danaher guided for 3% to 6% revenue growth and adjusted EPS of $8.35 to $8.50 in 2026 as biopharma spending shows signs of recovery. Recent results included $6.8 billion in quarterly sales, 2.5% core revenue growth and $1.8 billion in free cash flow.
Mar 07, 2026
Danaher approved a $0.40 quarterly dividend and completed a $9.9 billion Masimo acquisition to expand into patient monitoring, while its Life Sciences segment operating profit fell 57% in 2025 to $520 million.
Feb 19, 2026
The UK and US announced a pharmaceuticals agreement featuring zero tariffs and a 25% increase in UK spending on innovative medicines. Major pharma M&A deals and regulatory reforms are reshaping the industry in early 2026.
